Anjana Pillai to Chemoembolization, Therapeutic
This is a "connection" page, showing publications Anjana Pillai has written about Chemoembolization, Therapeutic.
Connection Strength
3.043
-
Management of Intermediate-Stage Hepatocellular Carcinoma: Systemic Versus Locoregional Therapy. Surg Oncol Clin N Am. 2024 01; 33(1):159-172.
Score: 0.896
-
Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years? Clin Liver Dis. 2020 11; 24(4):681-700.
Score: 0.740
-
Hepatocellular Carcinoma: A Contemporary Approach to Locoregional Therapy. Am J Gastroenterol. 2020 11; 115(11):1733-1736.
Score: 0.740
-
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 2022 06; 10(6).
Score: 0.206
-
Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020 04; 18(4):974-983.
Score: 0.169
-
Goals and targets for personalized therapy for HCC. Hepatol Int. 2019 Mar; 13(2):125-137.
Score: 0.163
-
Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. J Gastroenterol Hepatol. 2015 Jul; 30(7):1167-74.
Score: 0.128